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Abstract
Pharmacogenomics describes interpatient genetic variability in drug responses. Information based on whole genome
sequencing will soon open up the field of pharmacogenomics and facilitate the use of genomic information relating to
drug metabolism and drug responses. We undertook a qualitative study, aiming to explore the potential barriers,
opportunities and challenges facing the implementation of pharmacogenomics into primary care. Semi-structured inter-
views were undertaken with 18 clinical participants (16 GPs and 2 other clinicians). All interviews were recorded and
transcribed verbatim. Using a thematic analysis approach, data items were coded, ordered and themes constructed. Most
participants were aged 55–60 years and worked as part-time clinical GPs with other clearly defined roles. The emerging
themes covered several areas of concern, including the following: the utility of pharmacogenomics and the value of
introducing such testing into primary care; how to educate the primary care workforce and ‘mainstream’
pharmacogenomics; the ethical, legal and social aspects of pharmacogenomics and its impact on patients; and potential
impacts on the healthcare system particularly around economics and informatics. Most participants had concerns about
pharmacogenomics and felt that there were a number of barriers and challenges to its implementation into routine
primary care. Most striking were their concerns around the cost-effectiveness of using pharmacogenomics in primary
care. At the same time most recognised the increasing availability of direct-to-consumer testing, and felt that this would
drive the need to understand the ethical and social implications of using genomic information in primary care. This study
has raised important issues that need to be considered when planning the implementation of pharmacogenomics into
clinical practice. Prior to the implementation of genomic testing into day-to-day practice in UK primary care, it is
important that considerations around education, cost-effectiveness and informatics are addressed, as well as the impact
on patients.
Background
The 100,000 Genome project is a translational research pro-
ject (Genomics England n.d.) which is stimulating NHS
clinicians, researchers and policymakers to consider how ge-
nomic medicine will be mainstreamed across all specialties,
including General Practice. Health Education England (HEE)
is addressing this concern by evaluating the genomics educa-
tional needs of General Practitioners (GPs) through surveys
and feedbacks (HEE Genomics Programme: Engaging
Primary Care n.d.). The use of genomic information at the
time of drug prescribing is a potential application, but one that
is not currently implemented in any systematic way in UK
clinical practice. ‘Pharmacogenomics’ describes the effect of
the genome on drug response. There is acceptance that while
the future implementation of prescribing based on the use of
genomic data is likely, we will need to consider key issues
such as clinical effectiveness and cost-effectiveness (Hillman
and Dale 2017; Hayward et al. 2017; Walter et al. 2014) be-
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Why is the study of pharmacogenomics clinically
useful?
Whole-genome sequencing (WGS) and other more targeted
forms of genotyping are beginning to enable testing for rele-
vant specific genetic variants that influence drug-prescribing
choices; these, in turn, can be personalised to the individual.
This is important for both drug efficacy and drug safety.
The risk of an adverse event should be used to aid
choice of both drug and dosage (Ventola 2013) and poten-
tially reduce toxicity. This is important since the clinical
and economic cost to the NHS is high when 6–7% of hos-
pital admissions are due to adverse drug reactions (Adverse
Drug reactions- summary n.d.). The PRACTICE Study re-
ported that 30% and 47% of patients receiving 5 or more
and 10 or more medications, respectively, had prescribing
or monitoring errors in a 12-month study period (Avery
et al. 2013).
Drug dose and response can be determined by an individ-
ual’s drug metabolizing capacity (Adverse Drug reactions-
summary n.d.; Professor Bill Newman 2017). Enzyme sys-
tems such as cytochrome p450 provide examples of this var-
iability, as they influence commonly prescribed drugs such as
tamoxifen (CYP2D6), codeine (CYP2D6) and clopidrogel
(CYP2C19) (Chang et al. 2015). Research looking at rates
of hospitalisation in a primary care population showed that
patients who were ultra-rapid CYP2D6 metabolisers had an
increased rate of hospitalisation compared with CYP2D6 ex-
tensive metabolisers (Takahashi et al. 2017). Another key ex-
ample is anticoagulation, as randomised controlled trials have
shown that genotype-guided warfarin dosing is superior to
standard dosing with respect to the time in the therapeutic
INR range (Pirmohamed et al. 2013; Dahal et al. 2015).
Further work in UK primary care examining this issue is on-
going (Kendrick et al. 2017).
GPs are not likely to be aware of The Clinical
Pharmacogenetics Implementation Consortium (The Clinical
Pharmacogenetics Implementation Consortium n.d.) (CPIC),
which is working to produce guidelines that use genomic data
that may lead to actionable prescribing decisions for specific
drugs. This is an initiative that uses the Pharmacogenomics
Knowledge Base resource (Pharmacogenomics Knowledge
Base resource 2017) around the impact of genetic variation
on drug response.
GP views around the use of genomic information and its
value to clinical care are therefore important to understand
(Bouwman et al. 2009; Christensen et al. 2016), in order to
deliver effective implementation of pharmacogenomics ap-
proaches into routine clinical practice in primary care. The
aim of this hypothesis-generating qualitative study was to
identify potential barriers, challenges and opportunities to




Recruitment was undertaken using a convenience sample,
with most participants known professionally to the researcher
(IR) either as clinical, academic or RCGP colleagues. Most of
the participants were approached either face-to-face or by cor-
respondence. A study information sheet was provided to in-
troduce the work.
Data collection
All participants were verbally consented, and afterwards pro-
vided with a written consent form. All agreed to audio-
recording of the interview (see “Appendix” for the interview
guide). The interviews were conducted by telephone between
April and June 2017 at the interviewee’s convenience. Each
interview lasted up to 60 min and was guided by a short topic
guide, developed specifically for this study and informed by a
literature review. Each transcript was transcribed by an author
(IR or DR), and then sent to the participant for any feedback or
clarification; only two participants opted not to receive and
comment on their transcript. Explicitly personal identifiable
information were not included in the data analysis or study
reports.
Analytical approach
Data were subjected to a thematic analytic approach (Ritchie
et al. 2003). The transcripts were read multiple times by the
first author (IR), with any early themes colour-highlighted.
During the analysis process, codes were attached to sections
of excerpts of interview transcripts, inter-related, and then
linked ideas emerging from the transcripts were combined
together as sub-themes. These sub-themes were subsequently
grouped into a more encompassing draft thematic framework.
Following an iterative review carried out by another author
(FW), the final framework was agreed upon.
Results
Participants
A total of 18 people were interviewed, with the majority being
GPs (n = 16). Although the GPs’ modal age group was 50–
59 years, efforts were made to recruit early career GPs to
interview a spectrum of participants by age and therefore
length of service. Most of the GPs worked as part-time clini-
cians, often combining this with other professional roles such
as academic or policy work; one was a recently retired GP. A
scientific curator (age 30–39, 12 years as a scientist) and a
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public health medicine researcher (age 50–59 years, 20 years
as a public health researcher) were also interviewed.
Thematic framework
Seven broad themes emerged from the analysis and are de-
tailed as follows:
1. Pharmacogenomics: could it be useful in general
practice?
The key issues to emerge were a lack of knowledge and
awareness and concerns around the evidence-base and utility
of the data that might be used. ‘I’ve not heard the term
(Pharmacogenomics), it’s something new to me’ (R15,
Locum GP), and ‘I think those terms do make sense but even
I don’t know the difference between genetics and genomics, so
I wouldn’t know what pharmacogenetics is as opposed to
pharmacogenomics’ (R11, academic GP). ‘I think one of the
challenges is about what level of evidence do we need to
justify using these tests in routine practice…. If you look at
the randomised controlled trials, they provide a degree of
justification in terms of informing those, but not so much in
terms of reducing clinical adverse effects’ (R13, academic
GP).
These data suggest that GPs may have little knowledge
around pharmacogenomics, and there is therefore a general
need for information about what contribution genomics could
offer to improve the safety and effectiveness of prescribing in
routine clinical primary care.
2. How will patient factors influence implementation?
Many interviewees made interesting observations around
patient factors influencing pharmacogenomics, including the
effects of personalised medicine and its impact on patient
perspectives and shared decision-making. They valued
patient-centred care but were anxious around extra workload
pressures following implementation of personalised medicine.
Genetics was seen as one of several elements contributing
to ‘personalising medicine’, ‘personalised medicine is about
interpreting all the things in your context, the genetic element
is one element, and it’s not the overriding element’ (R4, infor-
matics expert). The application of pharmacogenomics in
personalised medicine was apparent to many. ‘I think GPs
would be wise to understand, or at least be familiar with,
the new role of genetic information in personalising medica-
tion’ (R2, RCGP clinical lead).
Patient anxiety and workload pressures were also important
considerations. ‘So yes, it’ll definitely create more work I think
both for us and for secondary care as well, and probably
increase patient anxiety if they come wanting to know the
significance of information’ (R15 Locum GP). Any
interviewee mentioned, ‘there’s something a bit ethical about
it as well in terms of exactly what genomic data you are
getting and whether there’s any data that predicts future risk
that you may or may not want to have known’ (R17, Clinical
Lead).
Presentation of the evidence to patients was consid-
ered important for a meaningful discussion, and the im-
portance of shared decision making was raised by some,
’you have still got to develop a shared understanding of
it between you; you have still got to have the same pro-
cess of shared decision making’ (R10, GP Academic),
and ‘I think it’s something about the general area
around informed choice and rational decision’ (R5,
Public Health Researcher).
3. How important is pharmacogenomics education?
Many felt that the level of pharmacogenomics knowl-
edge that a primary care healthcare professional might
need would vary depending on the level of complexity
around clinical management they were responsible for,
‘we are talking about different responses to drugs
which will include a more detailed understanding of
the genetic issues’ (R2, GP with informatics knowledge).
Professional differences and needs were also highlight-
ed. ‘Practice GPs will seek education about it; ...anoth-
er driver which is really crucial is the RCGP curricu-
lum’ (R9, GPSI genetics).
Patients knowledge and beliefs were considered by many,
‘My patient cohorts are quite well informed – they educate me
a lot of the time’ (R16, Clinical Fellow). Others mentioned the
traditional approach of an expert opinion as the best source of
information, ‘always really grateful when someone came in to
talk to us about say BRCA risk or something like that – it filled
the gap’ (R16,Clinical Fellow). Some people felt that ‘under-
standing of genetics is very variable, and people have all sorts
of belief about the terms genetics and what genes and gene
tests can tell them.’ (R9 GPSI genetics).
Some felt that involving other health care professionals
such as pharmacists would be important, and it would require
uniform dissemination of genomics education and competen-
cy needs. ‘The other aspect is to take it out of the hands of
GPs, and delegate to nurse practitioners or pharmacists, they
would do it, [so] wider MDT sharing of role, this might be
something that a pharmacist do it in a practice [especially] if
doing large numbers at a time’ (R12, a RCGP medical
director).
Some focused on the vital role of education for successful
implementation: indeed, education was often considered to go
beyond the types of programmes aimed at either patients or
professionals. ‘I mean from an educational programme,
[would] have to put more through schools, universities, de-
grees you know, medical schools’ (R1,GP Principal).
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Responses here highlighted the importance of skill-mix
and delegation of roles which could underpin a strategic ap-
proach to the delivery of pharmacogenomics education.
4. What are the barriers to mainstreaming pharmacogenomics
in clinical practice?
The key challenge for the NHS was universally considered
to be how the use of genomic information could be
‘mainstreamed’ (i.e. as part of normal practice) into general
practice. It was clear that respondents thought that there would
need to be a pool of GPs who could offer advice. However, the
barriers to implementation included the fact that in General
Practice at present, only small numbers of GPs understand the
concepts. ‘It will be rare to find a GP who is up to speed with
pharmacogenomics... genomics whatever’ (R6, Academic
GP).
Many felt that there was a need for both individual training
and the ‘mainstreaming’ process facilitated through generat-
ing an expert pool in general practice: ‘[it would] make sense
to have a collaboration of Primary Care Physicians interested
around pharmacogenomics‘ (R3, RCGP lead) or that ‘every
GP would need some sort of training. Mainly brand new GPs
would have enough knowledge but I suspect not – maybe in 5
years’ time when it’s more in forefront but not yet’ (R1,GP
Principal). ‘But I think at the moment most GPs would need
lots of training to use it’ (R1,Clinical Fellow) and inherent
scepticism ‘..[just] think about trying to translate some of
the apparent promise of the approach into practice’ (R10,
Academic GP).
Despite the obvious barriers, there was some acceptance
that this was just likely to happen: ‘this is new and yes, it will
become mainstream, and it will become part of part of our
clinical decision-making like everything else, because it’s go-
ing to be’ (R7, Digital lead). ‘It could revolutionise our prac-
tice, it’s hugely exciting for the future and GPs, rather than
saying this is too much for us, we could be at the forefront of
this’ (R12, a RCGP medical director).
It was interesting that GPs perceived pharmacogenomics
tests being used as tool as part of day-to-day clinical practice
with the potential for General Practice to lead the way.
5. Social (and family) implications of pharmacogenomics
information
Many GPs were concerned about insurance loading for
relatively minor conditions, and that genomic data may be
used to make such decisions around insurance premiums that
could have potential repercussions for family members.
Genomic information was generally considered to be dif-
ferent to other forms of clinical information. For example,
‘insurance loading’, i.e. paying an extra premium based on
personal medical data is something that worries both patients
and GPs on behalf of their patients, and was frequently
discussed: ‘obviously it has implications for life insurance’
(R16, Clinical fellow). Of importance was how many GPs
anticipated insurance loading for what seemed relatively mi-
nor conditions.
The familial nature of genomic data was also frequently
highlighted: ‘I suppose the genetic component that needs
explaining is the repercussions for the family, any sort of
genetic information can’t be seen in isolation from the family’
(R6,GP academic).The tension between ownership of person-
al and family information and ‘societal’ ownership seemed
problematic: ‘So I would want to put that in, it’s owned by
society’ (R4, informatics expert), and: ‘there is social disparity
in requesting of (genetic) testing and accessing the testing and
that somehow that knowledge could have an effect on family
relationships. I think the issues around genomic data is
broader, and I think that’s around the impact it has on other
people and someone’s future health’ (R2, Clinical Lead).
Reflections like these highlight the perceived familial im-
portance of genomics and the considerations to be taken into
account around sharing.
6. Cost-effectiveness
With current workload pressures in UK general practice, it
was clear that incorporating genomics in practice with the
potential benefits was welcome provided the implementation
considered cost-effectiveness as a priority.
Issues such as commissioning decisions based on cost-
effectiveness were considered to be really important. The bal-
ance between financial costs, cost-effectiveness and opportu-
nity costs was mentioned by many participants: ‘If all these
things add up into patient benefits more than other interven-
tions of a similar opportunity costs and similar financial costs,
then good. But I wouldn’t want to [adopt it] just because it’s a
wonder of biotechnology’ (R11, GP academic), and: ‘I think
for primary care the key issues are going to be clinical utility
and cost effectiveness. There are some barriers in terms of
commissioning at the moment, and the way commissioning
is siloed is going to be one of the main barriers and those
are one of the main question marks over pharmacogenomics
before it’s mainstream’ (R9, GPSI genetics). However, the
current working environment was not considered ideal:
‘CCGs at the moment would be hugely concerned by the
workload… it’s a major workforce crisis across the country
and struggling to provide enough appointments to see people
at the moment, and the thought of having extra work for
GPs….’ (R1, a RCGP medical director).
Many felt that approaches to implementation built on
established models would be crucial. One felt that the UK
could learn about implementation from countries with differ-
ing healthcare systems. ‘The Dutch Pharmacogenomics work-
ing group have published guidelines for the clinician based on
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genotype’ (R8, Scientist). Many interviewees discussed the
value of testing in primary care, including examples of appli-
cation, improving efficacy whilst reducing toxicity and confi-
dence in the use of such approaches. There was some discus-
sion about how pharmacogenomics could offer value, and it
was generally deemed to be dependent on the available exper-
tise: ‘I think it will be more important for things like antico-
agulants, side effects, cancer therapies, less so for antihyper-
tensive and statins’ (R5, Public Health Researcher).
There was general agreement about the potential of using a
pharmacogenomics approach: ‘to be able to prescribe medi-
cines with a confidence that [it brings]‘ (R4, informatics
expert), and ‘To have a better outcome, target people more
effectively’ (R1, GP Principal). ‘Anything that would help
efficacy, it would definitely have the potential to be taken up
by GPs.’ (R9, GPSI genetics’. This point was important and
relevant to the discussion about supporting implementation
into practice.
7. Informatics
There was agreement about the importance of elec-
tronic capture of genomic information, anxiety around a
new coding system and concern around the principles of
data sharing.
Interviewees discussed the application of informatics
to pharmacogenomics. In particular, the sensitivity of
personal genomics information recorded on a patient’s
primary care electronic health record: ‘it’s the record
that is kept by the patient, follows the patient unlike
hospital systems’ (R1, GP principal). Many felt that
limitations around expertise in coding could be an issue:
‘I would be worried about would be the coding within
the system to make sure we are correctly capturing the
right information’ (R1, GP Principal), with concerns
that the information being recorded could be highly
sensitive: ‘concerns about data security is higher with
genetic data because it has implications on a criminal
type of basis not just for the data subject’ (R4, infor-
matics expert). There was frustration that the recording
of family history has not been a success, and some
questioned whether genomic information be recorded
more successfully. ‘The reality is we’re talking about
genomic information [yet] we haven’t even got decent
family history data so how are we going to use geno-
mics if we can’t even incorporate family history?’ (R14,
Locum GP). Furthermore, new coding systems due for
implementation do not appear to incorporate plans for
recording or coding. ‘SNOMED CT codes, the one that
are supposed to be integrated in primary care [soon],
they are absolutely not adequate in recording genomic
information. They are very patchy, [and] relate to only
certain codes’ (R9, GPSI genetics).
‘it is potentially a problem I think... if the implications of
the genomics test affects family members, because we are very
good at recording in one patient’s notes but actually because
of confidentiality etc. it’s very difficult to ensure all the right
people have cross referencing for that result.’ (R12, a RCGP




This interview study investigating the implementation of
pharmacogenomics into UK General Practice has
highlighted a number of barriers and challenges.
Although some participants recognised the potential op-
portunities for pharmacogenomics, they all recognised
the implementation challenges such as harnessing the
utility of pharmacogenomics and the value of introduc-
ing such testing into primary care. Other issues that
were considered were around how to educate the prima-
ry care workforce and ‘mainstream’ pharmacogenomics.
Also of importance were the ethical, legal and social
aspects of pharmacogenomics and its impact on
patients, and potential impacts on the healthcare system
particularly around cost-effectiveness and informatics.
Comparison with existing literature
These findings from interviews with UK clinicians cor-
relate with findings from other countries, for example
with Canadian primary care providers’ perceptions
around personalised genomic medicine (Carroll et al.
2016). The themes raised may be of particular use to
policy makers and commissioners. In order to translate
and implement findings from pharmacogenomics re-
search into clinical practice, a multi-pronged approach
will be needed (Bartlett et al. 2014). Ideally, this should
be facilitated by tailored education for primary care cli-
nicians, and the development of electronic decision sup-
port systems to enable the integration of genomic and
clinical information into the clinical healthcare records
(Julia et al. 2010). Beyond the NHS, there are other
drivers to clinician and patient ‘mainstreaming’ of
pharmacogenomics including commercial companies and
the private sector. Direct to consumer genomic (DTC)
testing is now widely available, and our findings confirm
that there is commercial variation around how such ge-
nomic data are handled or utilised, not only in the UK
but also from an international perspective(Baroncini et al.
2016; Rafi et al. 2009; Bernhardt et al. 2012; Bartlett
et al. 2012). Patients are increasingly using these
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approaches, and their reasons, such as having a family
history of a disease, may enable them to feel empowered
by holding this type of pharmacogenomics information
(van der Wouden et al. 2016).
Our findings demonstrated that appropriate genomics edu-
cational needs of primary care clinicians should be provided,
to facilitate understanding of the utility and value of a novel
approach to patient management, such as pharmacogenomics,
before implementation can be successful. While the Gen-
Equip (Paneque et al. 2017) modules of education provide a
good resource for European GPs, our findings suggest that
information needs to be timely, easily available and succinct.
A multi-faceted approach has been promoted as a means of
engagement for both GPs (Houwink et al. 2015; Lopes-Junior
et al. 2017) and other clinicians including pharmacists and
secondary care clinicians (Johansen Taber and Dikinson
2014).
‘Mainstreaming’ pharmacogenomics into the NHS is likely
to require expert clinical support. As clinical genetics are un-
likely to have the capacity to manage demand (Blashki et al.
2014), secondary care physicians (for example, clinical phar-
macologists) will need to perform pharmacogenomics testing
and support primary care. This has been simulated in the USA
which improved physician’s confidence in prescribing deci-
sions (Overby et al. 2015). However, the lack of clinical
knowledge when adding genomic information to US primary
care workload has been evaluated in a pilot randomised trial
and indicated that WGS may prompt the primary care provid-
er to initiate clinical actions of unclear value. For example, if
screening was initiated, or detailed advice given, to change
healthcare behaviour for a perceived increase risk in cardio-
vascular disease or diabetes, when that risk was not above
population risk (Vassy et al. 2017).
The findings also demonstrated a range of views around the
ethical, legal and social factors surrounding pharmacogenomics.
While some felt that pharmacogenomic information was no dif-
ferent to other healthcare data with regard to confidentiality and
sharing with external bodies, others felt that such data were sen-
sitive personal data which need to be managed carefully with the
potential for discrimination, particularly around insurance
(Wauters and Van Hoyweghen 2016). These issues are going
to be particularly pertinent in the setting of the General Data
Protection Regulation (EU) 2016/679. In North Carolina, USA,
insurers have recently declined cover for WGS (although
pharmacogenomics testing could be done without WGS), as its
utility was considered low. There was also concern about the
impact of pharmacogenomics on shared decision-making, simi-
lar to the findings from a recent US study which demonstrated
the importance of purpose, context and deliberation when incor-
porating genomic risk assessments into population screening pro-
grams (Nicholls et al. 2016). This study suggested that members
of a target patient population could engage meaningfully about
their acceptability and utility of genomic information (Nicholls
et al. 2016). In another study, there was limited discussion on
how different populations (ethnic differences) might react to their
metaboliser status which might lead to exclusion of drug pre-
scribing for that individual (Kaphingst et al. 2015).
Our study findings demonstrated the known implementa-
tion challenges for all genetic and genomics advances
(Wauters and Van Hoyweghen 2016), namely the need for
an evidence base (including the relative importance of ethnic-
ity in pharmacogenomics clinical decision making), more ex-
perience with testing, facilitated integration into the electronic
medical record and enhanced knowledge and understanding
by clinicians as well as by patients. Real-life examples of
where pharmacogenomics has been implemented with pre-
emptive genotyping in the USA include the Vanderbilt and
St. Jude Children’s Research Hospital and will provide the
basis to overcoming these implementation challenges in the
UK NHS (Manolio et al. 2013).
Strengths and limitations of the study
This was one of the first studies to explore GP views on
pharmacogenomics in the UK. The participants were pre-
dominantly GPs working in the UK and included a spec-
trum of GPs at different stages of their careers. Using a
qualitative approach, with individual interviews, enabled
an in-depth understanding and elucidation of the barriers
and facili tators to successful implementation of
pharmacogenomics in UK primary care practice.
Recruitment of more participants, both GPs and other
clinicians such as practice nurses and pharmacists, might
further our understanding. These early findings from a
small participant group could be further explored and
confirmed with a larger survey, aiming to recruit a more
representative group of primary care clinicians.
Implications for practice
Clinical decision support may represent the optimal model
to utilise genomic information; this applies to a general
practice population both in the UK and internationally.
The barriers to implementation ranged from lack of knowl-
edge, to issues relating to storage and access of informa-
tion, to clinical utility underpinned by an evidence base.
There was recognition that reducing toxicity after drug
administration was beneficial. With the lack of a body of
support, professional GPs may feel that the implementation
of pharmacogenomics may not be optimal. Barriers to im-
plementation identified under the main themes are not
unique to General Practice (Saul et al. 2017; McGrath
and Ghersi 2016), and are also barriers to mainstreaming
genomic practice among staff affiliated with primary care
such as practice nurses (Brennan 2015) and pharmacists
(Clemerson et al. 2006; Haga et al. 2016). However, the
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opportunities in implementation includes personalising
medicine, to reduce toxicity, to enhance the efficacy of
drugs and to use genome guided therapy in the setting of
polypharmacy (Swinglehurst and Fudge 2017).
The Chief Medical Officer’s (CMO) recently published
report on genomics, entitled Generation Genomics
(Genomics and Therapeutics 2017), has a genomics and ther-
apeutics theme which identifies the potential for stratified
medicine so that new drug targets are identified and exploited
for therapeutics which in turn can affect drug dosing and drug
safety.
The future (next 5–10 years) holds the promise of advanc-
ing the use of genomic information in mainstream medicine
and prescribing. The benefits include reduced toxicity and
better efficacy. This will require a concerted effort with col-
laborative working between primary care, NHS England,
Heath Education England, the UK Pharmacogenetics
Stratified Medicines Network, NHS Digital and Clinical
Genetics and others including the Royal Pharmaceutical
Society to facilitate adoption.
The findings in this study cover broad generic issues that
could equally be considered and extrapolated to other health
care systems in other countries. We envisage that further stud-
ies around implementation that analyse each of the themed
issues found in this study could inform the use of
pharmacogenomics testing into clinical medicine that could
lead to greater efficacy and reduced adverse drug events.
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Appendix. Semi-structured interviews
Developing a Road Map for the implementation
of Pharmacogenomics into UK General Practice:
barriers, challenges and opportunities
What do you understand about the termpharmacogenomics?
Do you think it is a term that would be easily understand by
most GPs?
How do you think pharmacogenomics could help or hin-
der the GP in day to day practice (efficacy, reducing
toxicity, time commitment, workflows?)
What do you think could be the challenges in the use of
genomic data? (clinical utility, interpretation,
understanding).
Are there any tests based on genomic information that is
or could be helpful to practice?
What are the necessary steps in terms of the use of geno-
mic information in GP prescribing and treatment optimi-
sation? (informatics, cost, timely etc.).
What are the potential barriers to such implementation
(patient factors?)
What recommendations would you make based on the
informatics needs of practices and practitioners.
What will be necessary and need to be provided by the
primary care IT system providers?
Are there any education or training needs?
Is there anything else you feel is relevant to the
discussion?
Thank you.
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